COMMUNIQUÉS West-GlobeNewswire
-
TAP Sleep Care Groundbreaking Dual Therapy: Mouth Shield + TAP Improves Oral, Cardiac, and Cognitive Health in OSA
24/02/2026 -
OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
24/02/2026 -
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
24/02/2026 -
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
24/02/2026 -
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
24/02/2026 -
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
24/02/2026 -
ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
24/02/2026 -
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
24/02/2026 -
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
24/02/2026 -
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
24/02/2026 -
Alkeus Pharmaceuticals Announces Presentation of Investigational Oral Gildeuretinol Data During the 49th Annual Meeting of the Macula Society Being Held February 25-28
24/02/2026 -
Disc Medicine to Participate in Upcoming Investor Conferences
24/02/2026 -
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
24/02/2026 -
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02/2026 -
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026 -
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026 -
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
24/02/2026 -
Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development
24/02/2026 -
Porosome Therapeutics Announces New Porosome-Targeted Medicines Developed Using AI
24/02/2026
Pages